Dermapharm Holding SE

XTRA:DMP Voorraadrapport

Marktkapitalisatie: €1.7b

Dermapharm Holding Inkomsten in het verleden

Verleden criteriumcontroles 2/6

Dermapharm Holding is de winst gegroeid met een gemiddeld jaarlijks percentage van 4.9%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 13.1%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 12.1% per jaar. Het rendement op eigen vermogen van Dermapharm Holding is 14.5%, en het heeft een nettomarge van 7.2%.

Belangrijke informatie

4.9%

Groei van de winst

4.9%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie7.3%
Inkomstengroei12.1%
Rendement op eigen vermogen14.5%
Nettomarge7.2%
Volgende winstupdate14 Nov 2024

Recente prestatie-updates uit het verleden

Recent updates

Here's Why Dermapharm Holding (ETR:DMP) Has A Meaningful Debt Burden

Sep 28
Here's Why Dermapharm Holding (ETR:DMP) Has A Meaningful Debt Burden

Dermapharm Holding SE Beat Revenue Forecasts By 6.7%: Here's What Analysts Are Forecasting Next

Aug 31
Dermapharm Holding SE Beat Revenue Forecasts By 6.7%: Here's What Analysts Are Forecasting Next

Dermapharm Holding SE's (ETR:DMP) P/E Still Appears To Be Reasonable

Aug 17
Dermapharm Holding SE's (ETR:DMP) P/E Still Appears To Be Reasonable

It Looks Like Dermapharm Holding SE's (ETR:DMP) CEO May Expect Their Salary To Be Put Under The Microscope

Jun 21
It Looks Like Dermapharm Holding SE's (ETR:DMP) CEO May Expect Their Salary To Be Put Under The Microscope

These 4 Measures Indicate That Dermapharm Holding (ETR:DMP) Is Using Debt Extensively

Apr 29
These 4 Measures Indicate That Dermapharm Holding (ETR:DMP) Is Using Debt Extensively

Dermapharm Holding SE's (ETR:DMP) Price In Tune With Earnings

Feb 07
Dermapharm Holding SE's (ETR:DMP) Price In Tune With Earnings

Dermapharm Holding (ETR:DMP) Seems To Use Debt Quite Sensibly

Dec 15
Dermapharm Holding (ETR:DMP) Seems To Use Debt Quite Sensibly

An Intrinsic Calculation For Dermapharm Holding SE (ETR:DMP) Suggests It's 24% Undervalued

Nov 17
An Intrinsic Calculation For Dermapharm Holding SE (ETR:DMP) Suggests It's 24% Undervalued

Dermapharm Holding (ETR:DMP) Has A Pretty Healthy Balance Sheet

Aug 28
Dermapharm Holding (ETR:DMP) Has A Pretty Healthy Balance Sheet

Dermapharm Holding SE's (ETR:DMP) Intrinsic Value Is Potentially 76% Above Its Share Price

Aug 01
Dermapharm Holding SE's (ETR:DMP) Intrinsic Value Is Potentially 76% Above Its Share Price

Dermapharm Holding (ETR:DMP) Has A Pretty Healthy Balance Sheet

May 29
Dermapharm Holding (ETR:DMP) Has A Pretty Healthy Balance Sheet

Is Dermapharm Holding SE (ETR:DMP) Trading At A 44% Discount?

May 03
Is Dermapharm Holding SE (ETR:DMP) Trading At A 44% Discount?

Dermapharm Holding's (ETR:DMP) Soft Earnings Are Actually Better Than They Appear

Apr 04
Dermapharm Holding's (ETR:DMP) Soft Earnings Are Actually Better Than They Appear

We Think Dermapharm Holding (ETR:DMP) Can Stay On Top Of Its Debt

Feb 22
We Think Dermapharm Holding (ETR:DMP) Can Stay On Top Of Its Debt

Is Dermapharm Holding (ETR:DMP) A Risky Investment?

Nov 17
Is Dermapharm Holding (ETR:DMP) A Risky Investment?

Is Dermapharm Holding (ETR:DMP) A Risky Investment?

Aug 16
Is Dermapharm Holding (ETR:DMP) A Risky Investment?

Is Dermapharm Holding (ETR:DMP) A Risky Investment?

May 18
Is Dermapharm Holding (ETR:DMP) A Risky Investment?

Is Dermapharm Holding (ETR:DMP) Using Too Much Debt?

Feb 17
Is Dermapharm Holding (ETR:DMP) Using Too Much Debt?

These 4 Measures Indicate That Dermapharm Holding (ETR:DMP) Is Using Debt Reasonably Well

Nov 19
These 4 Measures Indicate That Dermapharm Holding (ETR:DMP) Is Using Debt Reasonably Well

Does Dermapharm Holding (ETR:DMP) Have A Healthy Balance Sheet?

Aug 21
Does Dermapharm Holding (ETR:DMP) Have A Healthy Balance Sheet?

Is Dermapharm Holding SE (ETR:DMP) Trading At A 28% Discount?

Jul 31
Is Dermapharm Holding SE (ETR:DMP) Trading At A 28% Discount?

Is Dermapharm Holding SE (ETR:DMP) The Right Choice For A Smart Dividend Investor?

May 03
Is Dermapharm Holding SE (ETR:DMP) The Right Choice For A Smart Dividend Investor?

Calculating The Intrinsic Value Of Dermapharm Holding SE (ETR:DMP)

Apr 16
Calculating The Intrinsic Value Of Dermapharm Holding SE (ETR:DMP)

Here's Why Dermapharm Holding (ETR:DMP) Can Manage Its Debt Responsibly

Mar 25
Here's Why Dermapharm Holding (ETR:DMP) Can Manage Its Debt Responsibly

Did You Miss Dermapharm Holding's (ETR:DMP) Impressive 110% Share Price Gain?

Mar 07
Did You Miss Dermapharm Holding's (ETR:DMP) Impressive 110% Share Price Gain?

Is Dermapharm Holding SE's (ETR:DMP) 27% ROE Better Than Average?

Feb 15
Is Dermapharm Holding SE's (ETR:DMP) 27% ROE Better Than Average?

Something To Consider Before Buying Dermapharm Holding SE (ETR:DMP) For The 1.4% Dividend

Jan 29
Something To Consider Before Buying Dermapharm Holding SE (ETR:DMP) For The 1.4% Dividend

Does Dermapharm Holding (ETR:DMP) Have A Healthy Balance Sheet?

Dec 24
Does Dermapharm Holding (ETR:DMP) Have A Healthy Balance Sheet?

The Dermapharm Holding (ETR:DMP) Share Price Has Gained 45% And Shareholders Are Hoping For More

Dec 07
The Dermapharm Holding (ETR:DMP) Share Price Has Gained 45% And Shareholders Are Hoping For More

Dermapharm Holding SE Just Missed Earnings - But Analysts Have Updated Their Models

Nov 18
Dermapharm Holding SE Just Missed Earnings - But Analysts Have Updated Their Models

Opbrengsten en kosten

Hoe Dermapharm Holding geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

XTRA:DMP Opbrengsten, kosten en inkomsten (EUR Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 241,147832820
31 Mar 241,129572740
31 Dec 231,151622710
30 Sep 231,172952480
30 Jun 231,1511232280
31 Mar 231,1281462120
31 Dec 221,0411341910
30 Sep 221,0241761850
30 Jun 221,0041851800
31 Mar 229802111730
31 Dec 219602101690
30 Sep 219021621680
30 Jun 218581231670
31 Mar 21828951680
31 Dec 20808861580
30 Sep 20775801420
30 Jun 20760771340
31 Mar 20743851190
31 Dec 19714771160
30 Sep 19674731140
30 Jun 19639771050
31 Mar 19611731000
31 Dec 1858475920
30 Sep 1855875960
30 Jun 1852576890
31 Mar 1849879820
31 Dec 1748078780
30 Sep 1748684700
31 Dec 1645577710
31 Dec 1539613650
31 Dec 144020670

Kwaliteitswinsten: DMP heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (7.2%) DMP } zijn lager dan vorig jaar (10.6%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: De winst van DMP is de afgelopen 5 jaar met 4.9% per jaar gegroeid.

Versnelling van de groei: De winstgroei DMP is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.

Winst versus industrie: DMP had het afgelopen jaar een negatieve winstgroei ( -32.3% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Pharmaceuticals ( 28.7% ).


Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 14.5% ) van DMP wordt als laag beschouwd.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden